Sodium Valproate: Health Education
Commons · Question 106958 · Tabled 20 Jan 2026 · Department of Health and Social Care · Official record
Answered 27 Jan 2026
Question
Asked by Bob Blackman
To ask the Secretary of State for Health and Social Care, what assessment has been made of the MHRA’s effectiveness at communicating known risks of sodium valproate, particularly in pregnancy, prior to 2018.
Answer
Answered by Zubir Ahmed, 27 Jan 2026
As with all medicines, the safety of valproate has been kept under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring the product information reflects what is known about valproate.The known risks of valproate are...